Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
Status:
Completed
Trial end date:
2012-12-20
Target enrollment:
Participant gender:
Summary
This study will assess the initial safety, tolerability, pharmacokinetics, and
pharmacodynamics of MK-8655, after single and multiple daily oral administrations to
participants with Type 2 Diabetes (T2DM). The study will assess the reduction in fasting
plasma glucose concentrations from baseline after multiple daily administrations of MK-8655.